Sharing KOL Insights in Co-Commercialization | Acceleration Point | Resources

Key Takeaways

Co-commercialization is a partnership in which two or more pharmaceutical companies jointly develop, market, and sell a product to share resources and reduce risk.
Key Opinion Leaders (KOLs) are recognized clinical experts whose input informs clinical trial planning, evidence interpretation, and scientific engagement across partners.
Bringing a new drug to market is capital-intensive: peer-reviewed analysis of FDA approvals from 2009 to 2018 put the median research and development investment at about $985 million.
Sharing KOL insights across co-commercialization partners is complicated by separate CRM systems, data-privacy requirements, and coordination gaps.
Integrated platforms, standardized data protocols, and clear communication frameworks help partners share KOL insights consistently and compliantly.

Bringing a new drug to market is no small feat. It requires careful planning, extensive research, and a solid pharmaceutical commercial strategy. To maximize their chances of success and reduce risk, many companies are now joining forces through co-commercialization agreements.

A central component of this approach is engaging Key Opinion Leaders (KOLs). These respected experts play an important role in shaping how new drugs are perceived, tested, and ultimately launched. The effective integration of KOL insights allows companies to identify key stakeholders, refine processes, and keep strategies aligned with industry demands.

In this article, we'll explore the impact of KOL engagement on commercialization agreements, its associated challenges, and how to strengthen pharmaceutical commercial strategy outcomes.

What Is Co-Commercialization in the Pharmaceutical Industry?

Co-commercialization involves a strategic partnership between two or more companies to jointly develop, market, and sell pharmaceutical products. In turn, these companies can share resources, identify market opportunities, and reduce risk in an increasingly competitive landscape.

The commercialization process typically consists of two primary phases:

Pre-launch: Focuses on branding, engagement, and achieving market access. Companies work with cross-functional teams to develop a clear value proposition and build relationships with payers, providers, and other stakeholders.
Post-launch: Involves monitoring real-world data, assessing outcomes, and adjusting strategies to support growth.

A well-defined launch strategy helps all partners within the commercial model align on brand messaging, regulatory requirements, and market positioning.

What Are the Main Challenges in Drug Co-Commercialization?

The drug co-commercialization process carries challenges that can impede the successful launch and adoption of new therapies. Opinion leaders play a pivotal role in addressing these obstacles and improving the effectiveness of co-commercialization efforts.

Before looking at how KOL insights can help, let's first identify the challenges in drug co-commercialization:

High development costs and time frames: In co-commercialization agreements, partners must balance financial investments while keeping cost and revenue-sharing structures equitable. Coordinating R&D efforts across multiple entities can add further complexity and delay. The stakes are significant: a peer-reviewed analysis of drugs approved between 2009 and 2018 estimated the median R&D investment to bring a new drug to market at about $985 million, counting the cost of failed trials.
Regulatory hurdles: Aligning regulatory strategies across multiple companies requires meticulous coordination to ensure compliance with different regulatory bodies. Divergent internal processes and data-sharing restrictions can further complicate regulatory submissions and approvals.
Market access and competition: Partners must present a unified value proposition to differentiate their product amid competition. Failure to align on pricing, reimbursement strategies, and messaging can hinder market entry.
Patient recruitment for clinical trials: Without coordinated communication, inefficiencies often arise when synchronizing clinical trial recruitment across partners. Varying site selection criteria and patient outreach strategies between collaborators can slow trial progress. Recruitment is already a well-documented bottleneck: a systematic review found that roughly 80% of clinical trials fail to meet their initial enrollment target and timeline.

How Do KOL Insights Help Companies Overcome These Challenges?

KOLs are respected experts in their fields who significantly influence medical practice and policy. Their insights are valuable throughout the drug development process, from planning clinical trials to observing how a therapy performs after it reaches the market.

An effective KOL engagement plan that incorporates structured coaching measures can help address the challenges described above in the following ways:

Enhanced credibility: By engaging respected KOLs, companies can present a unified and authoritative voice, reinforcing trust among healthcare professionals and patients while reducing inconsistencies in communication.
Informed decision-making: KOLs provide insights that help unify decision-making, keeping clinical trials, regulatory submissions, and product positioning aligned across all stakeholders.
Easier market adoption: KOLs help bridge potential gaps between partners by championing the therapy's benefits within the medical community, enhancing adoption, and reducing internal misalignment.
Improved patient recruitment: By drawing on their networks across different regions and institutions, KOLs support recruitment. This leads to a more efficient, coordinated approach that aligns with the joint commercialization strategy.

In co-commercialization agreements, the collective and effective engagement of KOLs by all partners makes the process of bringing a new drug to market smoother and more successful.

From Traditional to Digital: How KOL Engagement Is Changing

Digital technologies have reshaped how pharmaceutical companies engage with KOLs, particularly within co-commercialization agreements.

Traditionally, KOL engagement relied heavily on in-person meetings, conferences, and advisory board discussions. Digital tools have since emerged as a more efficient, scalable, and data-driven approach to managing these interactions across multiple partners.

Expanding global outreach

Digital platforms have removed geographical barriers, allowing pharmaceutical companies to collaborate with KOLs worldwide.

This global connectivity supports knowledge exchange and international market entry, which is particularly useful in co-commercialization agreements where multiple partners need access to the same insights across different regions.

Improving efficiency

Engaging KOLs through traditional methods often involves high costs, travel, logistics, and time-intensive planning. Digital solutions, including webinars, virtual conferences, and social media engagement, streamline communication and reduce expenses while enabling frequent and flexible collaboration.

This efficiency matters in co-commercialization, where multiple companies must align their outreach without redundant or conflicting messaging.

Using data-driven insights

Digital engagement tools provide real-time analytics and enable actionable insights from KOL social monitoring, as covered in Actionable Insights from KOL Social Monitoring. This data-driven approach helps ensure KOL insights are used effectively across all commercialization partners. Companies looking to formalize this can also review three digital ways to engage Key Opinion Leaders.

By using real-time reporting and integrated tracking, companies can refine their engagement strategies, improve decision-making, and allocate resources more effectively.

Personalizing engagement

Modern digital tools let pharmaceutical companies tailor outreach to individual KOL preferences. By selecting the most suitable communication channels and matching content to specific audiences, companies can build stronger relationships with KOLs.

In co-commercialization, this helps all partners deliver a cohesive and consistent engagement plan that aligns with their collective goals.

What Makes Sharing KOL Insights Difficult in Co-Commercialization?

While the advantages of co-commercialization are significant, one of the biggest hurdles is efficient sharing of KOL insights between partners.

Field teams often juggle multiple systems. They log interactions in their company's CRM, then switch to spreadsheets or other tools to document insights for joint collaboration.

This constant system switching disrupts workflow and leads to inefficiencies and frustration among team members. It is not the only challenge that comes with sharing KOL insights during co-commercialization.

Data silos

Each company in a commercialization agreement may use its own CRM, making it difficult to consolidate insights into a unified view.

Because partners rarely operate within the same system, critical information can become fragmented or inaccessible, slowing decision-making and reducing the effectiveness of KOL engagement.

Compliance and privacy concerns

Data protection regulations impose strict limits on how information can be exchanged between organizations. Companies need robust controls to keep sensitive data shared securely while remaining compliant with legal and regulatory requirements.

Coordination complexities

Complexities also arise when aligning engagement strategies. Without clear collaboration protocols, there is a risk of overcommunication with KOLs or conflicting messaging from different partners, which can undermine trust and credibility.

Ensuring engagement efforts are well-coordinated is essential to maintaining consistency and impact.

Addressing these challenges requires a strategic approach that integrates technology, standardizes data-sharing practices, and establishes a clear communication framework.

How Can Companies Share KOL Insights More Effectively?

To overcome the challenges that come with KOL insights in co-commercialization, pharmaceutical companies can apply the following strategies:

Integrated technology platforms: Using collaborative tools that connect with existing CRM systems supports consistent data sharing. Platforms like Kwello by Acceleration Point give medical teams real-time KOL interaction tracking, helping all partners work from up-to-date insights.
Standardized data protocols: Establishing common data formats and entry protocols supports consistency, making it easier to merge and analyze information from multiple sources.
Clear communication channels: Regular cross-partner meetings and updates support transparency and alignment, keeping all parties informed and coordinated.
Robust compliance frameworks: Comprehensive data-sharing agreements that outline compliance measures and privacy protections help reduce legal risk and build trust.
Collaborative engagement planning: Shared calendars and planning tools for KOL interactions prevent overlaps and support a balanced, strategic approach. A broader omnichannel engagement strategy can help partners keep touchpoints consistent.

FAQs

What is the pharmaceutical commercialization process?

The pharmaceutical commercialization process involves developing, marketing, and distributing a new drug, and securing the regulatory approval, market access, and broad adoption needed for it to reach patients.

What is a pharmaceutical business strategy?

A pharmaceutical business strategy is the long-term planning and execution of product development, pricing, marketing, and partnerships that guides how a company brings therapies to market.

What is KOL mapping?

KOL mapping is the process of transforming raw data into actionable insights about Key Opinion Leaders, allowing organizations to build stronger relationships with key influencers and support their strategic goals.

How do KOLs support co-commercialization agreements?

In co-commercialization agreements, KOLs support partners by reinforcing a unified and credible scientific voice, informing decisions across clinical trials and regulatory submissions, and helping coordinate engagement so partners avoid conflicting messaging.

What makes sharing KOL insights difficult across partners?

Sharing KOL insights across co-commercialization partners is difficult because each company often uses its own CRM, data-privacy regulations limit how information can be exchanged, and a lack of clear coordination protocols can lead to overcommunication or conflicting outreach.

Conclusion

In the pharmaceutical industry, the connection between co-commercialization agreements and KOL engagement is central to the successful launch and adoption of new therapies. Companies can strengthen their partnerships by proactively addressing the challenges of sharing KOL insights, often through integrated technologies, standardized protocols, and collaborative planning.

If your organization is working to improve KOL insight-sharing across co-commercialization partners, Acceleration Point's Medical Affairs consulting team can help you assess processes, apply technology more effectively, and set up systems that work when multiple companies need to share information.

Curious how this applies to your organization? Let's talk.

Pharmaceutical Commercial Strategy: Sharing KOL Insights in Co-Commercialization Agreements